tiprankstipranks
Sinopharm Tech Holdings Limited (HK:8156)
:8156
Hong Kong Market

Sinopharm Tech Holdings Limited (8156) AI Stock Analysis

0 Followers

Top Page

HK:8156

Sinopharm Tech Holdings Limited

(8156)

Select Model
Select Model
Select Model
Neutral 48 (OpenAI - 5.2)
Rating:48Neutral
Price Target:
HK$0.29
▲(30.45% Upside)
Action:ReiteratedDate:11/25/25
The overall stock score is primarily impacted by financial performance challenges, including negative equity and profitability issues. While technical analysis shows positive momentum, the valuation remains unattractive due to a negative P/E ratio. The absence of earnings call data and corporate events means these factors do not influence the score.
Positive Factors
Revenue Growth
Sustained, large revenue growth demonstrates meaningful market traction and recovery. Over the next 2-6 months this top-line expansion can provide the scale to invest in product and sales, enabling a transition from growth to durable margins if cost structure is managed.
Negative Factors
Negative Equity
Negative shareholders' equity and heavy leverage are structural balance-sheet weaknesses. Over a multi-month horizon they limit financial flexibility, raise refinancing and covenant risks, and constrain the company's ability to fund growth or absorb shocks without dilutive or costly financing.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Sustained, large revenue growth demonstrates meaningful market traction and recovery. Over the next 2-6 months this top-line expansion can provide the scale to invest in product and sales, enabling a transition from growth to durable margins if cost structure is managed.
Read all positive factors

Sinopharm Tech Holdings Limited (8156) vs. iShares MSCI Hong Kong ETF (EWH)

Sinopharm Tech Holdings Limited Business Overview & Revenue Model

Company Description
Sinopharm Tech Holdings Limited, an investment holding company, engages in lottery business in the People's Republic of China and Hong Kong. The company operates through Provision of Lottery-Related Services, Provision of Internet Plus Services, M...
How the Company Makes Money
null...

Sinopharm Tech Holdings Limited Financial Statement Overview

Summary
Sinopharm Tech Holdings Limited is experiencing strong revenue growth but faces significant profitability and financial stability challenges. The negative equity and high leverage are major concerns, while cash flow improvements offer some hope for recovery.
Income Statement
45
Neutral
Balance Sheet
30
Negative
Cash Flow
40
Negative
BreakdownJun 2024Jun 2023Jun 2022Jun 2021Jun 2020
Income Statement
Total Revenue61.25M41.28M42.84M40.98M77.81M
Gross Profit13.52M5.02M5.47M5.10M20.88M
EBITDA6.11M4.98M-1.01M-75.17M-89.65M
Net Income-867.00K-19.70M-10.63M-88.00M-106.34M
Balance Sheet
Total Assets51.74M44.49M33.48M76.89M135.90M
Cash, Cash Equivalents and Short-Term Investments6.95M2.64M1.78M2.99M7.48M
Total Debt46.73M73.26M53.00M45.93M108.03M
Total Liabilities88.43M250.09M213.24M250.28M276.46M
Stockholders Equity-36.87M-199.48M-172.73M-166.78M-138.88M
Cash Flow
Free Cash Flow-7.21M-12.58M4.73M-36.88M-16.32M
Operating Cash Flow-7.21M-9.25M4.73M-36.76M-6.21M
Investing Cash Flow-9.00K-4.86M2.00K-85.00K-5.05M
Financing Cash Flow11.50M14.98M-4.52M32.24M12.46M

Sinopharm Tech Holdings Limited Technical Analysis

Technical Analysis Sentiment
Negative
Last Price0.22
Price Trends
50DMA
0.30
Negative
100DMA
0.31
Negative
200DMA
0.29
Positive
Market Momentum
MACD
>-0.01
Positive
RSI
47.29
Neutral
STOCH
59.74
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:8156, the sentiment is Negative. The current price of 0.22 is below the 20-day moving average (MA) of 0.30, below the 50-day MA of 0.30, and below the 200-day MA of 0.29, indicating a neutral trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 47.29 is Neutral, neither overbought nor oversold. The STOCH value of 59.74 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:8156.

Sinopharm Tech Holdings Limited Peers Comparison

Overall Rating
UnderperformOutperform
Sector (61)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
61
Neutral
$37.18B12.37-10.20%1.83%8.50%-7.62%
56
Neutral
HK$29.06M-8.62-7.29%-14.25%77.78%
55
Neutral
HK$111.11M19.70-2.72%0.57%-13.40%76.97%
48
Neutral
HK$183.77M-12.91-1.65%48.39%88.30%
45
Neutral
HK$60.00M-105.56-1.21%-6.88%-100.00%
44
Neutral
HK$89.03M-21.75-47.29%-49.86%15.00%
42
Neutral
HK$30.57M6.10465.09%78.40%72.37%
* Technology Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
HK:8156
Sinopharm Tech Holdings Limited
0.29
0.18
163.64%
HK:8071
China Netcom Technology Holdings Limited
0.02
-0.02
-52.50%
HK:8036
eBroker Group Limited
0.03
-0.01
-33.33%
HK:8100
GET Holdings Limited
0.25
0.11
78.57%
HK:8131
abc Multiactive Limited
0.05
-0.03
-36.25%
HK:8290
Ahsay Backup Software Development Company Limited
0.03
0.01
66.67%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Nov 25, 2025